Search

Displaying results 3101 - 3110 of 3175 in total
  1. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated a...

    Categories: P-glycoprotein substrates
  2. Drug

    beta-Escin

    go.drugbank.com/drugs/DB15774
    Investigational

    Mixtures: Reparil Gel N
  3. Drug

    Fluocortolone pivalate

    go.drugbank.com/drugs/DB15777
    Investigational

    Mixtures: ULTRAPROCT N, ULTRAPROCT N
  4. Drug

    Chamazulene

    go.drugbank.com/drugs/DB15931
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  5. Drug

    Cinnamon oil

    go.drugbank.com/drugs/DB15986
    ApprovedInvestigational

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  6. Drug

    JBPOS0101

    go.drugbank.com/drugs/DB16034
    Investigational

    JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  7. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.

  8. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulato...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  9. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Nafithromycin

    go.drugbank.com/drugs/DB16246
    Investigational

    Nafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors